Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities

被引:17
作者
Klugman, KP
Low, DE
Metlay, J
Pechere, JC [1 ]
Weiss, K
机构
[1] Univ Geneva, Geneva, Switzerland
[2] Emory Univ, Rollins Sch Publ Hlth, Dept Int Hlth, Atlanta, GA 30322 USA
[3] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA
[4] Univ Witwatersrand, NICD, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa
[5] Mt Sinai Hosp, Dept Microbiol & Pathol, Toronto, ON M5G 1X5, Canada
[6] Univ Toronto, Toronto, ON M5G 1X5, Canada
[7] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
[8] VA Med Ctr, Philadelphia, PA 19104 USA
[9] Univ Marrakech, Marrakech, Morocco
[10] Univ Montreal, Fac Med, Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada
关键词
community-acquired pneumonia; S; pneumoniae;
D O I
10.1016/j.ijantimicag.2004.08.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Community-acquired pneumonia (CAP) is still one of the leading causes of mortality and morbidity. The most common bacterial cause of CAP is Streptococcus pneumoniae. The increase in antimicrobial resistance has raised concerns about the efficacy of available therapies, and a call for the reassessment of both existing and newer therapeutic agents. Although microbiological breakpoints are useful for monitoring the emergence of resistance, the current National Committee for Clinical Laboratory Standards (NCCLS) guidelines make no distinction between clinical and microbiological breakpoints. Recent changes in NCCLS breakpoints for extended spectrum cephalosporins have provided a more meaningful approach to susceptibility testing and to consideration of the site of infection. Further controversy surrounds the clinical guidelines relating to CAP in terms of which antimicrobial agents should be given empirically to which types of patients. Within this review, the role of monotherapy versus the need for combination antimicrobial therapy, which often includes a macrolide and an extended spectrum cephalosporin such as ceftriaxone, is discussed. This review also discusses the various aspects of antimicrobial susceptibilities of S. pneumoniae, the drivers and influences of increasing resistance, the clinical relevance of this resistance and possible therapeutic options in the face of changing susceptibilities and mixed bacterial aetiologies. New guidelines from the IDSA attempt to embrace these changes. (C) 2004 Published by Elsevier B.V. and the International Society of Chemotherapy.
引用
收藏
页码:411 / 422
页数:12
相关论文
共 102 条
[1]   Global antibiotic resistance in Streptococcus pneumoniae [J].
Adam, D .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :1-5
[2]   Molecular epidemiology of erythromycin resistance in Streptococcus pneumoniae isolates from blood and noninvasive sites [J].
Amezaga, MR ;
Carter, PE ;
Cash, P ;
McKenzie, H .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (09) :3313-3318
[3]   Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia [J].
Anderson, KB ;
Tan, JS ;
File, TM ;
DiPersio, JR ;
Willey, BM ;
Low, DE .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :376-381
[4]  
[Anonymous], 2003, TODAYS THER TRENDS
[5]  
[Anonymous], PERF STAND ANT SUSC
[6]   Antibiotic consumption and resistance selection in Streptococcus pneumoniae [J].
Baquero, F ;
Baquero-Artigao, G ;
Cantón, R ;
García-Rey, C .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :27-37
[7]   TRANSMISSION OF MULTIDRUG-RESISTANT SEROTYPE 23F STREPTOCOCCUS-PNEUMONIAE IN GROUP DAY-CARE - EVIDENCE SUGGESTING CAPSULAR TRANSFORMATION OF THE RESISTANT STRAIN IN-VIVO [J].
BARNES, DM ;
WHITTLER, S ;
GILLIGAN, PH ;
SOARES, S ;
TOMASZ, A ;
HENDERSON, FW .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :890-896
[8]   Prevalence of erm(A) and mef(B) erythromycin resistance determinants in isolates of Streptococcus pneumoniae from New Zealand [J].
Bean, DC ;
Klena, JD .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (04) :597-599
[9]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[10]   Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia [J].
Black, SB ;
Shinefield, HR ;
Ling, S ;
Hansen, J ;
Fireman, B ;
Spring, D ;
Noyes, J ;
Lewis, E ;
Ray, P ;
Lee, J ;
Hackell, J .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2002, 21 (09) :810-815